Skip to main content

Table 3 Tumor response

From: A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial)

  Level 1 (n = 3) Level 2 (n = 3) Level 3 (n = 6) Total (n = 12)
pCR rate 0% (0/3) 0% (0/3) 33.3% (2/6) 16.7% (2/12)
(95% CI: 4.70-44.80)
R0 rate 100% (3/3) 100% (3/3) 100% (6/6) 100% (12/12)
(95% CI: 75.8-100)
T downstaging (cT > pT) 66.7% (2/3) 100% (3/3) 50% (3/6) 66.7% (8/12)
N downstaging (cN > pN) 0.0% (0/3) 33.3% (1/3) 83.3% (5/6) 50% (6/12)
Down-staging 66.7% (2/3) 100% (3/3) 83.3% (5/6) 83.3% (10/12)
(95% CI: 55.2-95.3)